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Introduction
Staphylococcus aureus is the first etiological 
agent of osteomyelitis, a severe infection charac-
terized by progressive inflammation, bone tissue 
damage, and osteolysis.1,2 Although not consid-
ered as a typical intracellular pathogen, S. aureus 
was found capable to adhere to and to invade cul-
tured osteoblasts, as well as osteoblasts and to 
osteocytes in vivo.3
The ability of S. aureus to infect bone is tightly 
correlated to its ability to bind bone extracellular 
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matrix components, notably via multiple adhesins 
named microbial surface components. Through 
attachment, S. aureus can be internalized and sur-
vive within the cell switching notably to a small-
colony variant (SCV) phenotype. The presence of 
SCV has been highly associated with the develop-
ment of chronic and therapy-refractory infections.4 
Then, S. aureus or its components may potentially 
modulate the production of cytokines and 
chemokines, through binding to extracellular and/
or intracellular receptors. Infection with S. aureus 
eventually induces inflammatory cell recruitment, 
which, combined with increased osteoclastogenesis 
and osteoblast death, leads to a massive bone loss.5
The internalization within host cells acts pro-
tecting bacteria from the host immune response as 
well as from the medical treatments, as eukaryotic 
cells are often impermeable to conventional extra-
cellular antibiotics.6 Furthermore, it was demon-
strated that cultured osteoblasts infected with 
bacteria secrete immune modulators of the inflam-
matory response, namely, chemokine and cytokine 
molecules, which trigger and feed bone inflamma-
tion and destruction.7,8
In this study, we investigate new approaches that 
might be used to counteract internalization of osteo-
blasts by S. aureus and the consequent inflamma-
tory stimulation of the osteoclastogenesis process. 
We focus our attention on serratiopeptidase (SPEP), 
an extracellular metalloprotease already used as an 
anti-inflammatory agent.9 Moreover, it has also been 
shown to modulate adhesin expression and to 
enhance antibiotic efficacy toward biofilm-forming 
bacteria, and to interfere with S. aureus adhesion to 
both abiotic surfaces and epithelial cells.10,11
Methods
Bacterial strains and culture conditions
Bacterial strains used in this work were the follow-
ing: S. aureus ATCC 6538P (DSMZ 346), refer-
ence strain for antimicrobial testing; S. aureus 
ATCC 25923 (DSM 1104), clinical isolate and ref-
erence strain for antimicrobial testing; S. aureus 
ATCC 12598 (DSM 20372), clinical isolate from 
septic arthritis and reference strain belonging to 
ATCC collection; and S. aureus pi99, clinical iso-
late from orthopedic implant infection. Strains 
used were already characterized for genes coding 
for surface proteins relevant for adhesion and inter-
nalization to eukaryotic cells.10 Brain heart 
infusion broth (BHI; Oxoid, UK) was used for the 
planktonic cultures of S. aureus strains, which 
were grown under vigorous agitation at 37°C.
Eukaryotic cells
The human osteoblast cell line MG-6312 was cultured 
in minimal essential medium with Earle’s balanced 
salt solution (MEM/EBSS), supplemented with 10% 
fetal calf serum (FCS), 1% glutamine and 1% penicil-
lin–streptomycin in an atmosphere of 95% air, and 
5% CO2 at 37°C. All media were from Euroclone, 
Italy. Monolayers were used 48 h after seeding.
Chemicals
SPEP (2540 U mg−1), obtained from Takeda Italia 
Farmaceutici (Italy), was dissolved in phosphate-
buffered saline (PBS; pH 7.2) at a stock concentra-
tion of 20,000 U mL−1 and stored at −20°C.
Cellular infections in vitro
Staphylococcal strains from 18 h cultures in BHI 
broth, were grown in the absence of SPEP. 
Subsequently, bacteria were diluted at 1:100 in 
BHI and sub-cultured up to OD600 = 1.0 at 37°C 
with or without 200 U mL−1 SPEP (SPEP-pretreated 
and SPEP-untreated bacteria, respectively). Before 
infection, human osteoblast cells were maintained 
in basal medium containing 10% FCS without 
antibiotic (penicillin–streptomycin) for 24 h at 
37°C and 5% CO2. Subsequently, human cells cul-
tured in 24-well plates (BD Falcon, USA) to obtain 
semi-confluent monolayers (1.75 × 105 cells/well) 
were separately infected with 0.05 mL of SPEP-
pretreated and SPEP-untreated bacterial suspen-
sion at a multiplicity of infection (MOI) of about 
30 bacteria per cell (MOI 30:1) for 2 h at 37°C and 
5% CO2.
After incubation, osteoblast cell monolayers were 
washed with PBS, and 0.5 mL of fresh medium con-
taining 50 µg/mL of gentamicin was added to each 
well and incubated for 1 h at 37°C and 5% CO2 to 
kill extracellular bacteria. First, the sensitivity of 
bacteria to gentamicin was verified, as well as the 
non-toxicity toward MG-63 cells. Cells were then 
lysed by the addition of 0.025% Triton X-100 and 
the collected supernatants were plated on tryptic soy 
agar (TSA; Oxoid, UK) followed by an overnight 
incubation at 37°C to count viable intracellular bac-
teria. The internalization efficiency is expressed as 
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the percentage of the inoculated bacteria. Data repre-
sent the mean of three independent experiments.
Cell proliferation and cell viability
For cell proliferation experiments, osteoblasts were 
incubated with staphylococcal strains. The infection 
was performed as previously described. After incu-
bation, the number of living cells was determined by 
colorimetric 3-(4,5-dimethythiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide (MTT) assay (Sigma-
Aldrich, Italy). After removing the supernatant, the 
resulting intracellular purple formazan was solubi-
lized with dimethyl sulfoxide (DMSO) and spectro-
photometrically quantified at 560 nm. Uninfected 
osteoblasts were used as a control. All experiments 
were performed with or without SPEP. The results 
were expressed as the mean percentage in compari-
son with no infected cells. The cell viability was 
also assessed by Trypan Blue exclusion dye.13
Measurement of cytokine concentration
The release of pro-inflammatory chemokine 
MCP-1 was evaluated after the exposure of the 
osteoblast cells to staphylococcal strains. Following 
the incubation, the concentration of the chemokine 
was determined in the culture supernatants by an 
enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s recommended 
procedure (Thermo Fisher, Life Technologies Italia 
Fil, Italy). As positive control, cells stimulated 
with lipopolysaccharide (LPS) from Escherichia 
coli 055:B5 (Sigma-Aldrich) were used.
Statistical analysis
The significance of the differences in the results of 
each test and the relative control values was deter-
mined with Student’s t-test. Values of p < 0.05 
were considered statistically significant. The data 
are the means of three independent experiments.
Results
SPEP action on staphylococcal internalization of 
osteoblasts
Preliminary experiments were addressed to assess 
the cytotoxicity of SPEP on MG-63 cells using the 
same SPEP concentration adopted in the internali-
zation assays (200 U mL−1). Cell morphology, via-
bility, and proliferation remained unaffected by 
SPEP treatments.
At first, the ability of S. aureus strains to invade 
MG-63 cells was evaluated. The four strains of S. 
aureus turned out endowed with a moderate capabil-
ity to internalize. The internalization efficiency of 
untreated S. aureus strains is reported in Figure 1. 
The internalization efficiency of S. aureus was 
slightly differing depending on the strain (0.23% ± 
0.00% for S. aureus 6538P; 0.40% ± 0.17% for S. 
aureus 25923; 0.45% ± 0.00% for S. aureus 20372; 
and 0.79% ± 0.29% for S. aureus pi99, see Figure 1).
In the subsequent experiments, the internalization 
efficiency of SPEP-pretreated bacteria was com-
pared with that of SPEP-untreated bacteria. 
Conversely, when bacteria were pretreated with 
SPEP, they showed a different behavior. In particu-
lar, as shown in Figure 1, the internalization effi-
ciency was neatly reduced for all SPEP-pretreated S. 
aureus strains, and with the only exception of the S. 
aureus 20372 strain, the reduction by the SPEP treat-
ment turned out statistically significant (Figure 1).
SPEP did not interfere with the internalization 
process of S. aureus in MG-63 cells when it was 
added on the cells during the infection (data not 
shown). In a previous work, we performed a 
genetic analysis of these bacterial strains in order 
to highlight the presence of genes coding for sur-
face proteins affecting the adherence capability. 
Despite results obtained here, S. aureus 20372 
strain showed the same protein pattern in terms of 
Atl, FnbA, ClfA, and SdrC of other tested strains.10
Results obtained seemed to stress the hypothesis 
the effect of SPEP is on bacterial invasive features 
rather than on eukaryotic cells permeability to the 
infection.
Figure 1. Effect of SPEP on cell internalization. MG-63 
cells were infected with S. aureus strains at an MOI of 
30:1 pretreated and untreated with SPEP, respectively. 
Internalization efficiency is expressed as the percentage of the 
initial inoculum of internalized bacteria that were gentamicin 
resistant 1 h post-infection. Data represent the mean of three 
independent experiments (*p < 0.05).
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SPEP action on osteoblast proliferation
At first, an assay was performed to evaluate the effect 
of SPEP on the proliferation of MG-63 cells in the 
absence of bacteria in order to exclude a condition-
ing of osteoblast proliferation due to the protease 
(data not shown). The proliferation remained unaf-
fected following SPEP treatment. Then, the effect of 
bacterial strains pretreated or untreated with SPEP 
on proliferation of MG-63 was assessed. Figure 2 
shows MG-63 proliferation in the presence of S. 
aureus strains reported as percentage in comparison 
with untreated cells (100%). Conversely to data 
reported in literature, after 24 h of incubation, a sig-
nificant increase in osteoblasts proliferation, com-
pared to that of the cells alone, was observed for S. 
aureus 6538P and S. aureus 20372. This experiment 
was performed in triplicate and results obtained have 
been statistically validated. We could tempt to 
explain this result, considering that nowadays the 
relationship between osteoblast response to S. aureus 
is not completely defined. More efforts are necessary 
to decipher which components are able to whether 
decrease or increase osteoblastic activity.5
When bacteria were pretreated with SPEP, a 
slight, statistically non-significant, decrease of 
proliferation was observed for all S. aureus strains.
Effect of SPEP on chemokine release
In order to evaluate the levels of expression for 
chemokine MCP-1 after staphylococcal infection, 
a specific ELISA test was performed. Figure 3 
shows MCP-1 levels in supernatants from MG-63 
cells infected with S. aureus strains after 24 h of 
incubation. As expected, a significant increase in 
MCP-1 released compared to those of the cells cul-
tured alone (basal level) was observed. In the basal 
level, in fact, the MCP-1 levels were 155.7 ± 55.2 
pg mL−1. Cells stimulated with LPS and uninfected 
and unstimulated cells were used as controls. 
Furthermore, the levels of MCP-1 in MG-63 cells 
cultured in the presence of LPS and SPEP were 
also evaluated. This latter represents a control 
of the responsiveness of the cells and the anti- 
inflammatory potential of SPEP. As expected, fol-
lowing the treatment with the anti-inflammatory 
molecule, the production of MCP-1 was signifi-
cantly diminished level decrease (230.8 ± 140.3 vs 
1465.1 ± 196.5 pg mL−1).
Afterwards, the content of chemokine MCP-1 in 
osteoblasts infected with SPEP-pretreated and 
SPEP-untreated S. aureus was also evaluated, 
respectively. Results obtained are reported in 
Figure 3. MCP-1 levels in supernatants derived 
from MG-63 cells infected with SPEP-pretreated 
S. aureus strains were slightly lower than superna-
tants derived from MG-63 cells infected with 
SPEP-untreated bacteria. This difference was 
shared by all four S. aureus strains and turned out 
statistically significant for two of them (namely, S. 
aureus 25923 and S. aureus pi99; Figure 3). This 
result is a consequence of the reduced internaliza-
tion of SPEP-pretreated bacteria: lower internali-
zation leads less stimulation and lower production 
of MCP-1.
Discussion
Several studies have also demonstrated that S. 
aureus can invade bone cells and so evade antimi-
crobial therapy.4–6 The intracellular persistence of 
S. aureus in bone cells may facilitate chronic bone 
infection. Therefore, the discovery of new mole-
cules able to impair internalization of osteoblasts 
and to control immune response is an important 
step toward the infection control.
In this article, the capacity of SPEP to affect the 
staphylococcal internalization of bone cells and to 
regulate the proliferation and the production of a 
Figure 2. Effect of SPEP on cell proliferation. Osteoblasts were 
incubated with S. aureus strains pretreated or untreated with 
SPEP. Proliferation was determined by a colorimetric MTT assay 
(OD at 560 nm) after 24 h of culture of infected and uninfected 
cells. Results were expressed as percentages of values normalized 
with control (100%). The control represents the cells incubated 
with medium alone. Data are represented as the means and 
standard deviations of three independent experiments.
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pro-inflammatory molecule by infected osteoblasts 
was investigated. Although the main roles of osteo-
blasts are the synthesis of bone components and 
the regulation of osteoclasts activity, it was demon-
strated that osteoblasts infected with bacteria 
secrete inflammatory cytokines and chemokines 
that contribute to feed inflammation and promote 
bone destruction.7 For this reason, we have chosen 
to monitor MCP-1 release because this chemokine 
is involved in the recruitment of osteoclasts and 
monocytes/macrophages (but also of neutrophils 
and lymphocytes), when eukaryotic cells are 
exposed to bacteria.
Our data show that when S. aureus actively 
invades and persists within human osteoblastic 
cells, there is an increase in MCP-1 levels. SPEP 
pre-treatment of the bacteria significantly reduced 
their internalization for three out of four of the 
investigated S. aureus strains. Furthermore, the 
levels of MCP-1 released by osteoblasts infected 
with SPEP-pretreated bacteria were lower than 
those observed in cells infected with untreated 
bacteria.
The use of SPEP in synergy with traditional 
antibiotics may be suggested as a good strategy to 
reduce the progression of infection in bone infec-
tion and control the progression of inflammatory 
diseases. Further in vitro and in vivo studies should 
support this view.
In conclusion, our research demonstrates that 
SPEP affects the ability of S. aureus to invade 
bone cells. Furthermore, it could modulate the 
inflammatory response by reducing the 
 production of chemokine MCP-1 notoriously 
involved in bone disease that contribute to bone 
destruction.
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